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Abstract: A previous publication of 57,311 pesticide applicators enrolled in the US 
Agricultural Health Study (AHS) produced disparate findings in relation to multiple myeloma 
risks in the period 1993–2001 and ever-use of glyphosate (32 cases of multiple myeloma in 
the full dataset of 54,315 applicators without adjustment for other variables: rate ratio (RR) 
1.1, 95% confidence interval (CI) 0.5 to 2.4; 22 cases of multiple myeloma in restricted dataset 
of 40,719 applicators with adjustment for other variables: RR 2.6, 95% CI 0.7 to 9.4).  
It seemed important to determine which result should be preferred. RRs for exposed and 
non-exposed subjects were calculated using Poisson regression; subjects with missing  
data were not excluded from the main analyses. Using the full dataset adjusted for age  
and gender the analysis produced a RR of 1.12 (95% CI 0.50 to 2.49) for ever-use of 
glyphosate. Additional adjustment for lifestyle factors and use of ten other pesticides had 
little effect (RR 1.24, 95% CI 0.52 to 2.94). There were no statistically significant trends for 
multiple myeloma risks in relation to reported cumulative days (or intensity weighted days) 
of glyphosate use. The doubling of risk reported previously arose from the use of an 
unrepresentative restricted dataset and analyses of the full dataset provides no convincing 
evidence in the AHS for a link between multiple myeloma risk and glyphosate use. 
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1. Introduction 
Glyphosate [N-(phosphonomethyl)glycine] is a broad-spectrum herbicide active ingredient, commonly 
sold as commercial formulations under a range of Roundup® branded products [1]. Data on the use of 
glyphosate and many other herbicides, insecticides, and fungicides were collected from 1993–1997 by 
researchers in a prospective cohort study of some 57,000 licensed pesticide applicators from the US 
States of Iowa and North Carolina [2]. At enrolment information was also sought on basic demographic 
data as well as information on smoking history, use of alcohol, and other lifestyle factors. Mortality and 
cancer incidence data are being collected by the AHS researchers and many publications have already 
appeared based on these data. The purpose of this secondary analysis is to understand the conflicting 
findings of De Roos and colleagues that have appeared on the risks of multiple myeloma in those 
applicators that have used glyphosate [3]. 
The above paper [3] contains two disparate findings for the risks of multiple myeloma in ever users of 
glyphosate, with cancer incidence data to the end of 2001: an unexceptional risk in 54,315 applicators in 
analyses that only adjusted for age (rate ratio or relative risk (RR) 1.1, 95% confidence interval (CI)  
0.5 to 2.4) and a non-significantly elevated risk in 49,211 applicators in analyses that also adjusted for level 
of education, smoking history, use of alcohol, history of cancer in first degree relatives, State of residence, 
and use of ten other pesticides (RR 2.6, 95% CI 0.7 to 9.4). The second finding, based on the smaller 
dataset, excluded applicators with missing data for any of the variables included in the analysis. Both 
findings excluded applicators diagnosed with cancer prior to enrollment into the AHS and applicators 
who did not know whether or not they had ever used glyphosate. It is most unusual to observe such 
differences in risk estimates derived from the same study (RRs of 1.1 and 2.6), and whilst the higher risk is 
not significantly elevated, glyphosate users, producers of glyphosate, and regulatory agencies need to 
understand how these differences came about and which result should be given more importance. These 
disparate findings have been highlighted previously in published correspondence [4,5]. 
Little is known about the causes of multiple myeloma. A recent review published in six parts by the 
International Agency for Research on Cancer (IARC) included an evaluation of the target sites for all the 
IARC Group I carcinogens [6–11]. The only carcinogen that showed sufficient evidence for producing 
multiple myeloma in humans was gamma radiation [9]. Limited evidence was found for exposures to 
benzene and ethylene oxide [11]. There have, however, been a number of studies reporting excess risks 
of multiple myeloma in connection with specific industries including farm workers [12,13]. 
2. Materials and Methods 
The secondary data file analysed in this report was kindly provided by AHS researchers and included 
no information on identifying particulars (names, addresses, dates of birth, or social security numbers). 
The file was not a copy of the entire AHS dataset but rather a copy of those variables used by De Roos et 
al. [3], except that data on race, State of residence, and applicator type were not supplied because of 
concerns that these variables could lead to the identification of study participants, and that any such 
identification would constitute an unwarranted invasion of privacy. AHS researchers supplied an 
informative description of the file and the file was found to be internally consistent as well as consistent 
with data descriptions supplied earlier [3]. All subjects gave their informed consent for inclusion before 
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they participated in the AHS study and ethics approval for the original data collection by AHS 
researchers was obtained from the Institutional Review Board of the National Institutes of Health; this 
secondary analysis was conducted in accordance with the Declaration of Helsinki and the protocol was 
approved by the University of Birmingham Science, Technology, Engineering and Mathematics Ethical 
Review Committee (project code ERN_11-0758, 20 July 2011). 
Cohort enrolment, and follow-up for the period 1993–2001, have been described previously [2,3]. In 
summary, data on lifestyle factors and use of pesticides were collected from 57,311 private and commercial 
pesticide applicators from Iowa and North Carolina. Previous analyses [3] were carried out on three 
subsets of data. The first set comprised 54,315 applicators and this was obtained by excluding applicators 
with any cancers diagnosed before enrolment (n = 1074), applicators lost to follow-up  
(n = 298), who had missing data for age at enrolment (n = 7), or who provided no information on whether 
they had ever used glyphosate (n = 1678); these exclusion categories are not mutually exclusive. The 
second set of data comprised 49,211 applicators and this was obtained by a further exclusion of applicators 
with missing data on level of education (a surrogate for socio-economic status) (n = 1296), smoking 
history (n = 1783), or use of alcohol (n = 2616); information was complete for State of residence (not 
available to current analysis), and family history of cancer in first degree relatives. The third set of data 
comprised 40,719 applicators and this was obtained by a further exclusion  
of applicators with missing data on either use or estimated cumulative exposure days for 2,4-D  
(2,4-dichlorophenoxy acetic acid) (n = 1202), alachlor (n = 3142), atrazine (n = 917), metolachlor  
(n = 2925), or trifluralin (n = 3203), missing data on ever-use of benomyl (n = 2467), maneb  
(n = 2674), paraquat (n = 2737), carbaryl (n = 1828), or diazinon (n = 2701).  
This analysis aimed to examine findings in as full a dataset as possible and some analyses have also 
been carried out on a larger fourth set of 55,934 applicators, a category that does not exclude applicators 
with missing data on ever-use of glyphosate but only applicators with cancers diagnosed before enrolment, 
applicators lost to follow-up, or who had missing data for age at enrolment. 
Poisson regression was used to estimate RRs and 95% CIs associated with glyphosate exposure 
metrics, with and without adjustment for other variables [14]. Each variable under analysis was classified 
into levels or categories. The analytical approach for the full dataset was to have a “not known/missing” 
category for each variable so that analyses of all available cases could be maintained. However it was 
necessary to ensure that there was at least one case of multiple myeloma in each level of each variable 
for the regression to successfully calculate RRs. There were no cases of multiple myeloma in those 
applicators with “unknown use of 2,4-D”; such applicators were combined with those reporting “no use” 
to create a new category of “no claim of use”. There were no cases of multiple myeloma in those 
applicators with “unknown level of education”; such applicators were combined with those reporting no 
education beyond high school. All significance tests were two-tailed and tests for trend (where 
applicable) were calculated by scoring the levels of a variable and treating the variable as unfactored. 
All analyses were performed with the EPICURE statistical software [15], using the double precision 
DOS version 2.12 of DATAB and AMFIT, dated March 2002. 
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3. Results 
Table 1 shows RRs for multiple myeloma in terms of reported ever-use of glyphosate. Findings are 
shown for the first three sets of applicators, there were 32 cases of multiple myeloma in Set 1, 26 cases in 
Set 2, and 22 in Set 3. There was no adjustment for gender in the findings in this Table, in order to follow 
the approach adopted by De Roos and colleagues [3]. The first column of RRs includes statistical 
adjustment for age at enrolment only (see Table 1 footnotes for levels), the second column includes 
additional adjustments. The Table summarises the results of five separate analyses. None of the point 
estimates is statistically significant and in Set 1, the largest data set, the RR for ever-use of glyphosate is 
close to unity (RR 1.08, 95% CI 0.48 to 2.41). The point estimates of risk for the smaller datasets show an 
approximate doubling of risk irrespective of whether adjustment for other variables is carried out; the 
largest RR is shown for the fully adjusted model of the smallest dataset. 
Table 1. Risks of multiple myeloma from the AHS in relation to use of glyphosate in three 
sets of data. 
Set a Subjects Multiple Myeloma Cases (n) RR b (95% CI) RR (95% CI) 
1 
Non-users 13,280 8 1.0    
Users 41,035 24 1.08 (0.48 to 2.41) -- -- 
Total 54,315 32     
2 
Non-users 11,881 4 1.0    
Users 37,330 22 1.91 (0.66 to 5.53) 2.07 c (0.71 to 6.04) 
Total 49,211 26     
3 
Non-users 9809 3 1.0    
Users 30,910 19 2.21 (0.65 to 7.48) 2.79 d (0.78 to 9.96) 
Total 40,719 22     
a Set 1 comprised 54,315 applicators excluding those with any cancers diagnosed before enrolment, applicators 
lost to follow-up, who had missing data for age at enrolment, or who provided no information on whether  
they had ever used glyphosate. Set 2 comprised 49,211 applicators and further excludes applicators with 
missing data on level of education, smoking history, or use of alcohol. Set 3 comprised 40,719 applicators and 
further excludes applicators with missing data on either use or estimated cumulative exposure days for 2,4-D (2,4-
dichlorophenoxy acetic acid), alachlor, atrazine, metolachlor, or trifluralin, and missing data on ever-use of 
benomyl, maneb, paraquat, carbaryl, or diazinon. b Adjusting for age at enrolment only (<50 years, 50–59 years, 60–
69 years, ≥70 years); c Further adjustment for cigarette smoking (never smoker, ≤12 pack years, >12 pack years) use of 
alcohol in year before enrolment (none, <72 drinks, ≥72 drinks, history of cancer in first degree relatives (no/yes), 
and level of education (≤ high school and not known, > high school); d Further adjustment for level of use of 2,4-
D, alachlor, atrazine, metolachlor, or trifluralin (all classified in terms of none, ≤ median reported cumulative days 
of use, >median reported cumulative days of use), and ever use of maneb, paraquat, carbaryl, diazinon and 
benomyl (all classified in terms of yes/no). 
Table 2 also shows RRs for multiple myeloma in terms of reported ever-use of glyphosate for the 
54,315 applicators in Set 1, with a total of 32 cases of multiple myeloma. The first column of RRs 
summarises the findings from 15 separate analyses in which each variable is analysed simultaneously 
with age at enrolment and gender. The second column of RRs summarises the findings from a single 
analysis in which all 15 variables are analysed simultaneously, also adjusting for age at enrolment and 
gender. The RR for ever-use of glyphosate, with adjustment for age at enrolment and gender only, is 
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close to unity (RR 1.12, 95% CI 0.50 to 2.49). The RR for ever-use of glyphosate is little changed with 
additional adjustment for all 14 other variables (RR 1.24, 95% CI 0.52 to 2.94). None of the point 
estimates of risk in the Table are statistically significant and there is no suggestion that smoking or 
alcohol use are risk factors for multiple myeloma. 
Table 2. Estimated risks of multiple myeloma from the AHS study in relation to use of 
pesticides and other variables (32 cases (29 males, 3 females) in 54,315 applicators,  
Set 1 data a). 
Variable Cases 
Separate Analysis b Simultaneous Analysis c 
RR (95% CI) RR (95% CI) 
Glyphosate use 
Never 8 1.0  1.0  
Ever 24 1.12 (0.50 to 2.49) 1.24 (0.52 to 2.94) 
Smoking 
Never 17 1.0  1.0  
≤12 pack years 5 0.63 (0.23 to 1.72) 0.66 (0.24 to 1.83) 
>12 pack years 7 0.66 (0.27 to 1.60) 0.66 (0.27 to 1.65) 
not known 3 1.77 (0.52 to 6.10) 1.57 (0.43 to 5.69) 
Alcohol in year before enrollment 
None 19 1.0  1.0  
<72 drinks 6 0.47 (0.18 to 1.18) 0.52 (0.20 to 1.36) 
≥72 drinks 4 0.47 (0.16 to 1.41) 0.55 (0.18 to 1.71) 
not known 3 0.94 (0.28 to 3.18) 1.73 (0.42 to 7.15) 
Family history of cancer 
No 15 1.0  1.0  
Yes 17 1.47 (0.74 to 2.95) 1.55 (0.76 to 3.16) 
Education 
≤high school (or not known) 26 1.0  1.0  
>high school 6 0.48 (0.19 to 1.20) 0.50 (0.20 to 1.26) 
2,4-D 
no claim d 12 1.0  1.0  
≤median use 10 0.57 (0.24 to 1.34) 0.46 (0.18 to 1.15) 
>median use 10 0.72 (0.30 to 1.72) 0.57 (0.21 to 1.60) 
Alachlor 
None 13 1.0  1.0  
≤median use 7 1.06 (0.42 to 2.70) 0.91 (0.33 to 2.55) 
>median use 8 1.26 (0.51 to 3.09) 1.10 (0.38 to 3.14) 
not known 4 0.89 (0.29 to 2.76) 0.71 (0.13 to 4.04) 
Atrazine 
None 8 1.0  1.0  
≤median use 11 1.61 (0.63 to 4.12) 1.68 (0.61 to 4.67) 
>median use 12 1.77 (0.69 to 4.51) 2.02 (0.67 to 6.10) 
not known 1 1.44 (0.18 to 11.6) 1.16 (0.14 to 9.86) 
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Table 2. Cont. 
Variable Cases 
Separate Analysis b Simultaneous Analysis c 
RR (95% CI) RR (95% CI) 
Metolachlor 
None 14 1.0  1.0  
≤median use 7 1.56 (0.62 to 3.91) 1.73 (0.62 to 4.77) 
>median use 6 1.38 (0.53 to 3.65) 1.57 (0.51 to 4.82) 
not known 5 1.28 (0.46 to 3.58) 2.84 (0.59 to 13.8) 
Trifluralin 
None 16 1.0  1.0  
≤median use 9 1.16 (0.51 to 2.65) 1.07 (0.43 to 2.63) 
>median use 4 0.59 (0.19 to 1.77) 0.47 (0.14 to 1.58) 
not known 3 0.59 (0.17 to 2.04) 0.52 (0.11 to 2.50) 
Maneb use 
Never 24 1.0  1.0  
Ever 4 1.12 (0.39 to 3.23) 1.56 (0.46 to 5.30) 
not known 4 0.81 (0.28 to 2.37) 2.46 (0.33 to 18.3) 
Paraquat use 
Never 21 1.0  1.0  
Ever 7 0.96 (0.41 to 2.27) 0.83 (0.33 to 2.10) 
not known 4 0.74 (0.25 to 2.19) 0.99 (0.15 to 6.49) 
Carbaryl use 
Never 7 1.0  1.0  
Ever 23 1.85 (0.79 to 4.34) 2.48 (0.99 to 6.21) 
not known 2 0.85 (0.17 to 4.15) 1.07 (0.13 to 8.91) 
Diazinon use 
Never 21 1.0  1.0  
Ever 7 0.60 (0.26 to 1.41) 0.50 (0.20 to 1.25) 
not known 4 0.66 (0.22 to 1.96) 0.78 (0.11 to 5.55) 
Benomyl use 
Never 26 1.0  1.0  
Ever 3 0.72 (0.22 to 2.39) 0.51 (0.13 to 2.03) 
not known 3 0.58 (0.17 to 1.95) 0.23 (0.02 to 2.46) 
a Set 1 comprised 54,315 applicators excluding those with any cancers diagnosed before enrolment, applicators 
lost to follow-up, who had missing data for age at enrolment, or who provided no information on whether they 
had ever used glyphosate. b Column summarises 15 separate analyses in which each variable is adjusted for 
age at enrolment (<50 years, 50–59 years, 60–69 years, ≥70 years) and gender; c Single simultaneous analysis 
of all 15 variables, also adjusting for age at enrolment and gender. d None and not known combined. 
Table 3 shows RR estimates for multiple myeloma in terms of levels of reported cumulative days of 
glyphosate use and levels of estimated intensity-weighted exposure days for the 54,315 applicators in 
Set 1. The latter exposure metric is in arbitrary units and has been developed by AHS researchers to 
make use of data collected on work practices. For each exposure metric three sets of RRs have been 
calculated; firstly adjusting for age at enrolment and gender, secondly with additional adjustment for 
cigarette smoking, use of alcohol, family history of cancer, and level of education, and thirdly with 
additional adjustment for use of ten other pesticides. The Table summarises findings from six separate 
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analyses. Two tests for trend were applied to each of these analyses, the first scored the levels of 
cumulative exposure as 1–4, the second scored the level by mean values (shown in Table 3 footnotes). 
There were no significant trends, but a non-significantly elevated RR was shown for the highest category 
of intensity-weighted exposure days in the fully adjusted model (RR 1.87, 95% CI 0.67 to 5.27). There 
were no cases of multiple myeloma in glyphosate users with unknown extent of use (see Table footnote 
for numbers of applicators). 
Table 3. Risks of multiple myeloma in relation to estimated glyphosate exposure (cumulative 
exposure days or intensity-weighted exposure days) (32 cases [29 males, 3 females] in 54,315 
applicators, Set 1 data a). 
Glyphosate Exposure n RR b (95% CI) RR c (95% CI) RR d (95% CI) 
Cumulative exposure days e 
Never used 8 1.0  1.0  1.0  
1–20 days 10 1.06 (0.42 to 2.70) 1.13 (0.44 to 2.88) 1.14 (0.43 to 3.03) 
21–56 days 8 1.34 (0.50 to 3.58) 1.50 (0.56 to 4.05) 1.52 (0.54 to 4.34) 
57–2678 days 6 1.08 (0.37 to 3.11) 1.23 (0.42 to 3.58) 1.38 (0.42 to 4.45) 
p-value for trend f  p > 0.50  p > 0.50  p = 0.48  
p-value for trend g  p > 0.50  p > 0.50  p > 0.50  
Intensity-weighted exposure days h 
Never used 8 1.0  1.0  1.0  
0.1–79.5 units 6 0.91 (0.31 to 2.62) 0.99 (0.34 to 2.86) 1.00 (0.33 to 3.00) 
79.6–337.1 units 8 1.12 (0.42 to 3.00) 1.22 (0.45 to 3.28) 1.27 (0.45 to 3.56) 
337.2–18,241 units 10 1.44 (0.57 to 3.67) 1.65 (0.64 to 4.24) 1.87 (0.67 to 5.27) 
p-value for trend f  p = 0.39  p = 0.27  p = 0.22  
p-value for trend i  p = 0.33  p = 0.24  p = 0.18  
a Set 1 comprised 54,315 applicators excluding those with any cancers diagnosed before enrolment, applicators 
lost to follow-up, who had missing data for age at enrolment, or who provided no information on whether they 
had ever used glyphosate; b Adjusting for age at enrolment (<50 years, 50–59 years, 60–69 years, ≥70 years), and 
gender; c Further adjustment for cigarette smoking, use of alcohol, family history of cancer, and education (for 
levels see Table 2); d Further adjustment for use of ten other pesticides (for levels see Table 2); e Excluding 659 
subjects who used glyphosate with unknown exposure estimate; f Four categories scored 1–4; g Four categories 
scored by mean exposures of 0.0, 8.75, 38.75, and 116.0 days respectively; h Excluding 1011 subjects who 
used glyphosate with unknown exposure estimate; i Four categories scored by mean exposures of 0.0, 38.38, 
161.7 and 788.8 units (level-days) respectively. 
Table 4 shows RR estimates for multiple myeloma in terms of levels of ever-use of glyphosate, 
reported cumulative days of glyphosate use, and estimated intensity-weighted exposure days for the 
55,934 applicators in Set 4 with a total of 34 cases of multiple myeloma. The table summarises the 
findings of three separate analyses (for the three exposure metrics) with adjustment for age at enrolment, 
gender, family history of cancer, and level of education. The risk of multiple myeloma in ever-users of 
glyphosate was close to unity (RR 1.18, 95% CI 0.36 to 8.20) and there were no significant trends with 
either of the two cumulative exposure metrics. The applicators excluded from the analysis summarised 
in Table 3 were not excluded from this Table because there were two cases of multiple myeloma in the 
combined category of “ever-use of glyphosate not known”, and “extent of use not known”. 
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Table 4. Risks of multiple myeloma in relation to estimated glyphosate exposure (ever-use 
cumulative exposure days or intensity-weighted exposure days) (34 cases (31 males,  
3 females) in 55,934 applicators, Set 4 data a). 
Glyphosate Exposure n RR b (95% CI) 
Glyphosate use 
Never 8 1.0  
Ever 24 1.18 (0.53 to 2.65) 
not known 2 1.71 (0.36 to 8.20) 
Cumulative exposure days 
Never used 8 1.0  
1–20 days 10 1.11 (0.44 to 2.83) 
21–56 days 8 1.45 (0.54 to 3.88) 
57–2678 days 6 1.17 (0.40 to 3.41) 
not known c 2 1.19 (0.25 to 5.65) 
p-value for trend d  p > 0.50  
p-value for trend e  p > 0.50  
Intensity-weighted exposure days 
Never used 8 1.0  
0.1–79.5 units 6 0.95 (0.33 to 2.75) 
79.6–337.1 units 8 1.19 (0.44 to 3.19) 
337.2–18,241 units 10 1.58 (0.62 to 4.05) 
not known c 2 1.04 (0.22 to 4.92) 
p-value for trend d  p = 0.30  
p-value for trend f  p =0.26  
a Set 4 comprised 54,934 applicators excluding those with any cancers diagnosed before enrolment, applicators 
lost to follow-up, or who had missing data for age at enrolment; b Adjusting for age at enrollment (<50 years,  
50–59 years, 60–69 years, ≥70 years), gender, family history of cancer, and education (for levels see Table 2); c 
Use or extent of use not known; d First four categories scored 1–4; e First four categories scored by mean 
exposures of 0.0, 8.75, 38.75, and 116.0 days, respectively; f First four categories scored by mean exposures of 
0.0, 38.38, 161.7 and 788.8 units (level-days), respectively. 
4. Discussion 
This study found no significant trends of multiple myeloma risk with reported cumulative days of 
glyphosate use and unexceptional point estimates of risk for ever-use of glyphosate. This was irrespective of 
whether the analyses had adjustment for a few basic variables (age and gender) or adjustment for many 
other lifestyle factors or pesticide exposures, as long as data on all available pesticide applicators was 
used. The suspiciously elevated RRs reported previously [3] arose from the use of restricted data sets 
that, probably by chance, turned out to be unrepresentative. These restrictions would seem to be 
unnecessary because there is no technical problem in dealing with missing data in Poisson regression. 
In addition the restrictions may be undesirable as potentially informative data on the exposure/outcome 
under investigation are being discarded. To be concrete, Set 2 had 9% fewer applicators than Set 1, but 
lost 50% (n = 4) of multiple myeloma cases in those applicators who had never used glyphosate. Two 
of these cases were excluded because they were without data on cigarette smoking and the remaining 
two cases were without data on use of alcohol. Set 3 had 25% fewer applicators than Set 1, but lost 63% 
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(n = 5) of multiple myeloma cases in those applicators who had never used glyphosate. These lost cases 
in the baseline category (never-users) gave a false impression of elevated rates in ever-users.  
The main reason for carrying out this analysis was to discover whether there are good reasons to give 
more weight to one of the two point estimates of risk (1.1 and 2.6) for ever-use of glyphosate reported 
previously. The answer must be the lower estimate, because it is based on the full data set and is, in fact, 
almost unaffected by simultaneous adjustment for other variables whereas the higher estimate is based 
on an unrepresentative (biased) dataset.  
The practice of restricting analyses to subjects with complete data for all variables is, perhaps,  
a procedure to be carried out with caution as it is clear from this example that such restrictions can lead to 
misleading findings. It also ignores the fact that findings for missing categories can often be interesting 
in their own right. For example in the AHS the data on smoking have merit because lung cancer risks 
are related to the reported smoking data. This relationship (predicted to be positive on the basis of other 
studies [10]) has been calculated by this author as follows: non-smokers RR 1.0  
(by definition); ≤12 pack-years RR 3.24, 95% CI 1.47 to 7.15, and >12 pack-years RR 22.1, 95% CI  
11.7 to 42.0. What is interesting is that the point estimate of RR is similarly elevated for the “smoking not 
known” category (RR 26.2, 95% CI 12.7 to 54.1). One possible explanation for this is that the “not known” 
category is comprised in the main by heavy smokers who are perhaps tired of being asked about their 
smoking habits. By excluding applicators with unknown smoking history one would not be excluding a 
random sample of the study cohort but rather a group of heavy smokers. Of course, such exclusion would 
not in itself produce a biased dataset. Such bias would only occur if the exclusion is related to exposure 
and outcome as happened here with the loss of an unusual percentage of cases of multiple myeloma in 
non-users of glyphosate.  
One problem with some of these analyses (Table 2 for example) is that many risk coefficients are being 
calculated simultaneously from a dataset that only comprises 32 cases. It is perhaps surprising that the 
fuller analyses have not produced more erratic results. Most attention could be given to the analyses with 
limited adjustment for other variables (Table 4 for example) because ideally one would like to have only 
true risk factors or surrogates for true risk factors in the model.  
A 2010 review of all AHS publications concluded that multiple myeloma was not associated with 
glyphosate exposure in the AHS [16]. Data on multiple myeloma risk and glyphosate use is also available in 
a later Canadian case-control study of 342 cases of multiple myeloma and 1506 population-based 
controls [17]. Details of pesticide exposures were collected by telephone interview for those subjects 
who reported exposure for at least ten hours per year. A non-significantly elevated RR was reported for 
glyphosate use based on 32 exposed cases (RR 1.22, 95% CI 0.77 to 1.93). A more detailed analysis of these 
Canadian data found a non-significant deficit in risk for light users (≤2 days per year) of glyphosate (RR 
0.72, 95% CI 0.39 to 1.32, 15 exposed cases) and an excess risk that approached statistical significance 
in heavier users (>2 days per year) (RR 2.04, 95%CI 0.98 to 4.23, 12 exposed cases) [18]. Such results 
could be obtained if recall bias led some exposed cases to overstate their annual use. Excess risks of 
multiple myeloma in farmers have been reported in meta-analyses of farm worker studies [12,13]. 
Possible explanations for such excesses include pesticide exposures and contacts with farm animals. A 
recent pooled analysis of five case-control studies from North America and Europe into the aetiology of 
multiple myeloma reported “equivocal results” in supporting or refuting earlier associations with 
occupational pesticide exposure [19]. 
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This study has the same limitations that have been noted previously [3], namely the relatively small 
number of cases of multiple myeloma available for analysis, and the absence of information on timing of 
pesticide exposure (other than before enrolment). In addition this new analysis was not able to adjust for 
State of residence. Follow-up data continues to accrue in the AHS and a total of 71 cases of multiple 
myeloma have now been identified to the end of 2006 in private applicators [20]. It will be important to 
use these data together with extended follow-ups to continue to monitor cancer risks in glyphosate users 
and other pesticide applicators and it is hoped that the current paper will encourage the use of full datasets 
rather than restricted datasets. 
5. Conclusions 
This secondary analysis of AHS data does not support the hypothesis that glyphosate use is a risk 
factor for multiple myeloma, and suggests that the practice of restricting analyses to subjects with 
complete data for all variables is perhaps not to be recommended. 
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